Evidence map›Paper›PMID 34129359›Full record

ArticleJCO global oncology2021

C/Can City Engagement Process: An Implementation Framework for Strengthening Cancer Care in Cities in Low- and Middle-Income Countries.

Silvina Frech, Rebecca Morton Doherty, Maria Cristina Lesmes Duque, Oscar Ramirez, Alicia Pomata, Angelica Samudio, Osei A Antwi, Yin Yin Htun, Rai Mra, Pe Thet Htoon and 9 more

Abstract read
In one paragraph

Article in JCO global oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Review
  6. Participant Evaluation of a Multi-disciplinary Oncology Preceptorship Training Program for Oncology Health Professionals from Kumasi, Ghana.Journal of cancer education : the official journal of the American Association for Cancer Education · 2024
    Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Silvina FrechCity Cancer Challenge, Geneva, Switzerland.ORCID 0000-0002-2134-1512
Rebecca Morton DohertyCity Cancer Challenge, Geneva, Switzerland.ORCID 0000-0002-1464-542X
Maria Cristina Lesmes DuqueGobernación de Valle del Cauca, Secretaria de Salud, Colombia.ORCID 0000-0002-5093-6849
Oscar RamirezFundación Pohema and Centro Medico Imbanaco, Cali, Colombia.ORCID 0000-0001-7635-7784
Alicia PomataPrograma Nacional de Control de Cáncer, Instituto Nacional del Cáncer, Ministerio de Salud Pública y Bienestar Social de Paraguay, Asunción, Paraguay.ORCID 0000-0001-6085-3783
Angelica SamudioHospital de Clínicas, Facultad de Ciencias Médicas, Universidad Nacional de Asunción, Asunción, Paraguay.
Osei A AntwiKumasi Metropolitan Assembly, Ghana.
Yin Yin HtunShwe Yaung Hnin Si Cancer Foundation, Yangon, Myanmar.
Rai MraYangon Medical Association, Yangon, Myanmar.
Pe Thet HtoonShwe Yaung Hnin Si Cancer Foundation, Yangon, Myanmar.
Ernest Baawuah Osei-BonsuOncology Directorate, Komfo Anokye Teaching Hospital, Kumasi, Ghana.
Rafaela Komorowski Dal MolinHospital Moinhos de Vento, Porto Alegre, Brazil.
Nana MeboniaNational Center for Disease Control and Public Health of Georgia and Tbilisi State Medical University, Tbilisi, Georgia.
Isabel MestresCity Cancer Challenge, Geneva, Switzerland.
Aung Naing SoeCity Cancer Challenge, Geneva, Switzerland.
Sophie Bussmann-KemdjoCity Cancer Challenge, Geneva, Switzerland.
Maria Fernanda NavarroCity Cancer Challenge, Geneva, Switzerland.ORCID 0000-0002-8561-6474
Susan HenshallCity Cancer Challenge, Geneva, Switzerland.ORCID 0000-0002-1293-0091
Rolando CamachoCity Cancer Challenge, Geneva, Switzerland.ORCID 0000-0002-8394-4327

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The effective implementation of locally adapted cancer care solutions in low- and middle-income countries continues to be a challenge in the face of fragmented and inadequately resourced health systems. Consequently, the translation of global cancer care targets to local action for patients has been severely constrained. City Cancer Challenge (C/Can) is leveraging the unique value of cities as enablers in a health systems response to cancer that prioritizes the needs of end users (patients, their caregivers and families, and health care providers). C/Can's City Engagement Process is an implementation framework whereby local stakeholders lead a staged city-wide process over a 2- to 3-year period to assess, plan, and execute locally adapted cancer care solutions. Herein, the development and implementation of the City Engagement Process Framework (CEPF) is presented, specifying the activities, outputs, processes, and indicators across the process life cycle. Lessons learned on the application of the framework in the first so-called Key Learning cities are shared, focusing on the early outputs from Cali, Colombia, the first city to join C/Can in 2017. Creating lasting change requires the creation of a high-trust environment to engage the right stakeholders as well as adapting to local context, leveraging local expertise, and fostering a sustainability mindset from the outset. In the short term, these early learnings inform the refinement of the approach in new cities. Over time, the implementation of this framework is expected to validate the proof-of-concept and contribute to a global evidence base for effective complex interventions to improve cancer care in low- and middle-income countries.

Indexed as

Developing CountriesNeoplasmsCitiesColombiaHumansIncome

Identifiers

PMID34129359
PMCPMC8457859

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.